China Botulinum Toxin Type A Market 2013-2017 & 2018-2022
DUBLIN, Jan. 8, 2019 /PRNewswire/ --
The "Investigation Report on China's Botulinum Toxin Type A Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.
As the most toxic one of the eight antigenic types of botulinum, Botulinum Toxin Type A can irreversibly unite with presynaptic membrane within one hour. The targeted striated muscle will be relaxed usually 48 to 72 hours after the injection of Botulinum Toxin Type A. And the effect is maximally visible seven to 14 days following injection. Such muscle relaxation usually lasts for three to six months but varies greatly among different people. For some people, it can last up to 18 months.
On Apr. 15, 2002, Botulinum Toxin Type A was approved by the FDA as a medical cosmetic that is injected to temporarily improve the appearance of moderate to severe glabellar lines. Later, some generic drugs appeared on the market. In addition to the imported Botulinum Toxin Type A (trade name: Botox) produced by Allergan, the Botulinum Toxin Type A products in China also include Botulinum Toxin Type A (trade name: Hengli) developed by Lanzhou Institute of Biological Products Co., Ltd.
In China, the medical use of Botulinum Toxin Type A is to treat adult blepharospasm and prosopospasm and some strabismuses, especially acute paralytic strabismus, concomitant strabismus, strabismus caused by endocrine diseases, and the strabismus that cannot be corrected surgically for those aged 12 and above. The incidence of facial neuropathy is increasing in China. Many people are attacked by prosopospasm when they are over-stressed or fatigued. Seeing global annual incidence of about 0.003%, facial neuropathy is more common in women than in men, and more common in middle-aged and elderly people than in people from other age groups.
However, more users of Botulinum Toxin Type A are women who pursue a thin face or less wrinkles. With more than 10 million cosmetic surgeries every year, the market size of medical beauty in China has exceeded USD 10 billion and is still growing. As the demand for Botulinum Toxin Type A is expanding, some medical institutions and beauty salons have begun to inject Botulinum Toxin Type A smuggled from South Korea, France, Germany, etc. for their customers. Although the Chinese government only approved the sale of Botox and Hengli, smuggled Botulinum Toxin Type A products are easily available in China.
It is expected that, with the development of China's economy, the rise of income, and the change of consumption habit, Chinese people will spend more in medical beauty, and the market size of Botulinum Toxin Type A will continue to grow in China in the next few years.
Key Topics Covered:
1 Relevant Concepts of Botulinum Toxin Type A
1.1 Indications for Botulinum Toxin Type A
1.2 Development of Botulinum Toxin Type A in China
1.3 Governmental Approval of Botulinum Toxin Type A in China
2 Sales of Botulinum Toxin Type A in China, 2013-2017
2.1 Sales Value of Botulinum Toxin Type A in China
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Botulinum Toxin Type A in China
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Botulinum Toxin Type A by Dosage Form in China, 2013-2017
3 Analysis on Major Manufacturers of Botulinum Toxin Type A in China, 2013-2017
3.1 Analysis on Market Share of Major Manufacturers of Botulinum Toxin Type A
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Allergan
3.2.1 Enterprise Profile
3.2.2 Sales of Allergan's Botulinum Toxin Type A in China
3.3 Lanzhou Institute of Biological Products Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Lanzhou Institute of Biological Products Co., Ltd.'s Botulinum Toxin Type A in China
3.4 Analysis on Botulinum Toxin Type A Illegally Sold in China
4 Prices of Botulinum Toxin Type A in China, 2017-2018
4.1 Allergan (Botox)
4.2 Lanzhou Institute of Biological Products Co., Ltd. (Hengli)
5 Prospect of China's Botulinum Toxin Type A Market, 2018-2022
5.1 Major Factors Influencing Development of China's Botulinum Toxin Type A Market
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
For more information about this report visit https://www.researchandmarkets.com/research/n6ldmt/china_botulinum?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article